Post-transplant lymphoproliferative disease: association with induction therapy?

摘要: In the last 2 decades, several polyclonal and monoclonal antibodies have been developed for induction therapy in early post solid-organ transplantation period. The use of these has associated, most part, with a decrease acute rejection rates. However, there simultaneous rise infectious complications, particularly incidence post-transplant lymphoproliferative disease (PTLD). Determinations adjusted odds ratios or relative risk yielded conflicting information regarding whether antibody agents increase PTLD. order to interpret results different studies, reader requires detailed knowledge types analyses performed characteristics populations studied. This article available data on PTLD after agents. While some studies suggest an increased use, other do not; are not conclusive either way at this time.